

1 **The implementation of a rapid sample preparation method**
2 **for the detection of SARS-CoV-2 in a diagnostic laboratory**
3 **in South Africa**

4
5 Gert Marais^{1,3*}, Michelle Naidoo^{1,3}, Nei-yuan Hsiao^{1,3}, Ziyaad Valley-Omar^{1,2}, Heidi Smuts^{1,3},
6 Diana Hardie^{1,3}

7
8 ¹Division of Medical Virology, University of Cape Town, Cape Town, Western Cape, South
9 Africa

10
11 ²Groote Schuur Hospital Tissue Immunology Diagnostic Laboratory, National Health
12 Laboratory Service, Cape Town, Western Cape, South Africa

13
14 ³Groote Schuur Hospital Virology Diagnostic Laboratory, National Health Laboratory Service,
15 Cape Town, Western Cape, South Africa

16
17 *Corresponding author

18 E-mail: gert.marais16@alumni.imperial.ac.uk (GM)

19

20

21 **Abstract**

22

23 The SARS-CoV-2 pandemic has resulted in shortages of both critical reagents for nucleic acid
24 purification and highly trained staff as supply chains are strained by high demand, public health
25 measures and frequent quarantining and isolation of staff. This created the need for alternate
26 workflows with limited reliance on specialised reagents, equipment and staff. We present here
27 the validation and implementation of such a workflow for preparing samples for downstream
28 SARS-CoV-2 RT-PCR using liquid handling robots. The rapid sample preparation technique
29 evaluated, which included sample centrifugation and heating prior to RT-PCR, showed a
30 97.37% (95% CI: 92.55-99.28%) positive percent agreement and 97.30% (95% CI: 90.67-
31 99.52%) negative percent agreement compared to nucleic acid purification-based testing. This
32 method was subsequently adopted as the primary sample preparation method in the Groote
33 Schuur Hospital Virology Diagnostic Laboratory in Cape Town, South Africa.

34

35 **Introduction**

36

37 Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), an emergent
38 betacoronavirus, was identified as a novel causative agent of severe pneumonia in Wuhan,
39 China in 2019 [1]. The capacity for person-to-person transmission was soon identified and the
40 ensuing pandemic has caused more than seventeen million cases at the time of submission [2].

41

42 Currently, diagnostic testing for SARS-CoV-2 relies on molecular techniques, primarily
43 reverse-transcriptase polymerase chain reaction (RT-PCR), from respiratory specimens [3].

44 The specialised equipment and reagents required to offer these tests at scale has placed

45 significant strain on worldwide supply chains of reagents. Public health measures put in place
46 in numerous countries, including travel restrictions, have further made planning for sustainable
47 service delivery difficult as laboratory stock orders may not be filled on time. These issues
48 motivate for the use of diagnostic workflows that favour locally or readily available reagents
49 to, at least partially, insulate supply chains from fluctuations in global demand and evolving
50 travel limiting public health measures. To address these issues, a number of laboratories have
51 successfully developed alternative sample preparation techniques which limit reagent needs
52 and avoid complex nucleic acid (NA) purification protocols [4-6]. There is also a significant
53 cost saving when the reagent-free direct heating method, as described by Fomsgaard and
54 Rosenstjerne [4], is used which will become critical if economic fallout from the pandemic
55 intensifies. Staff shortages in the laboratory are an inevitability as social distancing
56 requirements are implemented in concert with increasing demand for diagnostic testing. SARS-
57 CoV-2 outbreaks in the laboratory environment may also introduce unpredictable shortages of
58 critical staff further limiting the capacity of laboratories to offer predictable test turnaround
59 times. The necessary influx of new staff, who may have limited training or training in a related
60 field, can further compromise the reliability of diagnostic laboratory services as the capacity
61 for oversight and quality control is hindered by rapidly evolving testing demands and workflow
62 instability due to reagent shortages and potentially unreliable testing kits due to limited
63 regulatory oversight [7]. All these factors highlight the need for automated workflows that limit
64 the number of laboratory staff-dependent steps and in particular steps requiring specialised
65 training. Automation further limits human error such as sample switches and cross-
66 contamination and are generally amenable to greater degrees of workflow control due to
67 traceable instrument log files.

68

69 A chemical reagent-free heat-based rapid sample preparation (RSP) method for downstream
70 SARS-CoV-2 RT-PCR amplification is presented here optimised for use on automated liquid
71 handling robots.

72

73 **Materials and methods**

74

75 **Ethics**

76

77 Biological material of human origin was anonymised and all clinical and other personally
78 identifiable data delinked with only study specific sample identifiers used along with sample
79 SARS-CoV-2 assay performance data. Ethics approval for this work was granted by the
80 University of Cape Town Human Research Ethics Committee (HREC reference number:
81 335/2020).

82

83 **Sample selection**

84

85 Nasopharyngeal (NP) and oropharyngeal (OP) swabs sent dry or in saline to the National
86 Health Laboratory Service Virology Diagnostic Laboratory in Groote Schuur Hospital from its
87 standard referral area for SARS-CoV-2 testing were included. 115 samples which tested
88 positive and 80 samples which tested negative for SARS-CoV-2 by NA purification-based
89 commercial diagnostic assays in use at the diagnostic laboratory were selected. Spectrum bias
90 was avoided by selecting consecutive samples that tested positive by standard testing over two
91 discrete intervals of regular laboratory workflow. Samples that tested negative were selected

92 randomly from the same intervals. The diagnostic assays in use were the Abbott RealTime
93 SARS-CoV-2 Assay (Abbott Laboratories, USA) running on the Abbott m2000 RealTime
94 system and the Allplex™ 2019-nCoV assay (Seegene, South Korea). The assays were run as
95 per package insert. The Allplex™ 2019-nCoV assay was performed after sample NA
96 purification using the NucliSENS® easyMag® (bioMérieux, France) as per package insert.

97

98 **Rapid sample preparation**

99

100 Standard diagnostic testing sample preparation included placing NP or OP swabs in a 2ml
101 Sarstedt sample tube containing 1.5ml autoclaved 0.9% saline. If both a NP and OP swab or
102 multiple swabs of the same type was received, they were combined in a single tube. The swabs
103 were cut to fit in the tube. The tube was then vortexed for 10 seconds. The saline was used as
104 the sample input for downstream assays after which the tube was stored at 4°C. Stored tubes
105 from diagnostic samples were available for inclusion in the study.

106

107 Selected sample tubes were centrifuged at 16 000 g for 5 minutes and 50µl of the supernatant
108 was then pipetted into the wells of a 96-well PCR plate. The PCR wells were capped and the
109 plate incubated on a thermocycler at 98°C for 5 minutes followed by 4°C for 2 minutes. The
110 PCR plate was then briefly centrifuged and placed on a dedicated QIAgility (Qiagen, Germany)
111 liquid handling instrument for sample-addition.

112

113

114 **RT-PCR after rapid sample preparation**

115

116 Concurrent with sample preparation, a second dedicated QIAgility instrument was used for
117 Allplex™ 2019-nCoV assay master mix preparation and aliquoting into appropriate 8-well
118 PCR strips (Bio-Rad Laboratories, USA). Following master mix preparation, the PCR strips
119 were transferred to the sample-addition QIAgility instrument. The sample input volume and
120 master mix constituents are shown in Table 1.

121

122 **Table 1. RT-PCR reaction preparation**

	Volume per reaction (µl)
RNase-free Water	11.1
2019-nCoV MOM (primer and probe mix)	6
5X Real-time One-step Buffer	6
Real-time One-step Enzyme	2.4
Internal control (RP-IC)	1.5
Sample after centrifugation and heating	3
Total volume	30

123

124 After sample addition, the PCR strips were sealed and briefly centrifuged before being loaded
125 on a CFX96™ Real-Time PCR Detection System (Bio-Rad Laboratories, USA). The real-time
126 PCR cycling parameters recommended by the Allplex™ 2019-nCoV assay package insert were
127 used unchanged. Real-time data analysis was performed using the 2019-nCoV Viewer for Real
128 time Instruments V3 (Ver 3.18.005.003) software as per the Allplex™ 2019-nCoV assay
129 package insert.

130

131 If the internal control (RP-IC) was not detected with a cycle threshold (Ct) value <40, the
132 primary sample was retested with a decreased sample volume input. The sample input for
133 repeat testing and master mix constituents are shown in Table 2. The remainder of the protocol
134 was unchanged.

135

136 **Table 2. RT-PCR reaction preparation for repeat testing**

	Volume per reaction (µl)
RNase-free Water	12.1
2019-nCoV MOM (primer and probe mix)	6
5X Real-time One-step Buffer	6
Real-time One-step Enzyme	2.4
Internal control (RP-IC)	1.5
Sample after centrifugation and heating	2
Total volume	30

137

138 **Repeatability and analytical sensitivity**

139

140 Inter-assay reproducibility was assessed using 8 samples with Envelope (E) gene Ct values
141 ranging between 17.16 and 35.63, which were tested in triplicate 7 days after initial testing.
142 Intra-assay reproducibility was assessed by repeating 16 samples in triplicate. Samples were
143 stored at 4°C while awaiting repeat testing. To assess the relative analytical sensitivity of the
144 RSP method, a sample was selected and serially diluted with saline and tested with multiple
145 replicates at each dilution after both NA purification and RSP using the Allplex™ 2019-nCoV

146 assay. The dilution at which SARS-CoV-2 RNA could be detected with 95% confidence was
147 determined for each method by Probit analysis. The absolute analytical sensitivity of the RSP
148 method was calculated based on the relative analytical sensitivity compared to NA purification-
149 based detection.

150

151 **Statistical analysis and graphics**

152

153 Data visualisation and statistical analysis, including paired t-tests for comparison of target Ct
154 values, a Fisher's exact test for statistical significance determination of the positive percent
155 agreement (PPA) and negative percent agreement (NPA) with NA extraction-based testing and
156 the Wilson/Brown method for 95% confidence interval determination, was done using
157 GraphPad Prism version 8.4.2 for macOS, GraphPad Software, San Diego, California USA,
158 www.graphpad.com.

159 **Results and discussion**

160

161 115 samples which tested positive and 80 samples which tested negative for SARS-CoV-2 by
162 NA purification-based testing were tested using the RSP method. The Allplex™ 2019-nCoV
163 assay result after RSP correlated for 111 and 72 samples respectively as shown in Table 3. One
164 sample that tested positive and 6 samples that tested negative were excluded. Raw data is
165 shown in the S1 Appendix.

166

167 **Table 3. Contingency table used for positive and negative percent agreement with NA**
168 **purification-based testing calculation**

	Positive SARS-CoV-2 Abbott RealTime SARS-CoV-2 Assay or Seegene Allplex™ 2019-nCoV Assay NA Purification	Negative SARS-CoV-2 Abbott RealTime SARS-CoV-2 Assay or Seegene Allplex™ 2019-nCoV Assay NA Purification
Positive SARS-CoV-2, RSP method, Seegene Allplex™ 2019- nCoV Assay	111	2
Negative SARS-CoV-2, RSP method, Seegene Allplex™ 2019- nCoV Assay	3	72


169

170 The PPA and NPA of the RSP method with NA purification-based testing for SARS-CoV-2
171 demonstrated a P value of <0.0001. The PPA of the RSP method was 97.37% (95% CI: 92.55-
172 99.28%) and the NPA 97.30% (95% CI: 90.67-99.52%). The 6 negative samples that were
173 excluded from RSP testing and analysis were excluded because the internal control failed to
174 amplify primarily and after repeat testing with a reduced sample input volume. This was likely
175 due to sample-specific PCR inhibitors. The positive sample that was excluded could not be
176 tested by RSP due to breakdown of the nasopharyngeal swab leading to excessive viscosity.

177

178 The Ct values of individual targets of the Allplex™ 2019-nCoV assay were assessed for
179 samples prepared by NucliSENS® easyMag® NA purification and RSP. The E gene, RNA-

180 dependent RNA-polymerase (RdRp) gene and Nucleocapsid (N) gene targets had Ct values
181 that were significantly different with a P value of <0.0001 (Fig 1). The mean difference in Ct
182 values between RSP and NA purification was 2.148 (95% CI: 1.909-2.387) for the E gene,
183 3.271 (95% CI: 3.037-3.506) for the RdRp gene and 1.608 (95% CI: 1.407-1.809) for the N
184 gene, with RSP demonstrating a greater mean Ct value in each case.



185
186 **Fig 1. Comparison of target Ct values after RSP and NucliSENS® easyMag NA**
187 **purification.** The Ct values for the SARS-CoV-2 (A) Envelope (E), (B) RNA-dependent RNA-
188 polymerase (RdRp) and (C) Nucleocapsid (N) gene targets are shown for samples tested with
189 the Allplex™ 2019-nCoV assay after NucliSENS® easyMag® NA purification and RSP. The
190 difference in generated Ct values was found to be statistically significant in each case with a P
191 value of <0.0001 as determined by paired t-test.

192
193 The difference in mean Ct values between RSP and NA purification based testing allowed the
194 PPA to be further estimated as 95.96% (95% CI: 92.23-97.94%). This was done by
195 retrospectively reviewing the results of samples with target amplification between 1 April 2020


196 and 24 April 2020 that were prepared for testing by NucliSENS® easyMag® NA purification.
197 The mean Ct difference values for each gene target (E, RdRp, N) were added to their respective
198 target Ct value. If this generated a value above 40, that gene target was deemed unlikely to be
199 detected after RSP. If all three gene targets were deemed unlikely to be detected, the sample
200 was classified as an expected negative. 198 previously positive samples were assessed in this
201 manner and 8 were classified as RSP-expected negatives thus allowing the calculation of the
202 above estimated PPA.

203

204 The relative performance of the Abbott RealTime SARS-CoV-2 assay and the Allplex™ 2019-
205 nCoV assay after RSP is shown in Fig 2. The Abbott assay reports cycle number (CN) values
206 which are not equivalent to Ct values and thus are not directly comparable.

207

208



209

210 **Fig 2. Comparison of target Ct and CN values after RSP and testing with the Abbott**
211 **RealTime SARS-CoV-2 assay.** The Ct values for the SARS-CoV-2 Envelope, RNA-
212 dependent RNA-polymerase and Nucleocapsid gene targets are shown for samples tested with
213 the Allplex™ 2019-nCoV assay after RSP and CN values after testing with the Abbott
214 RealTime SARS-CoV-2 assay are shown. A plotted CN or Ct value of 40 indicates that
215 detectable amplification did not occur. The Abbott assay CN values are assay specific and not
216 directly comparable to Ct values, but are shown to demonstrate the performance of the
217 spectrum of selected samples.

218

219 The single false negative result from the RSP method when compared to NucliSENS®
220 easyMag® NA purification was from a sample that only tested positive for one of the three
221 Allplex™ 2019-nCoV targets, the N gene, with a Ct value of 36.7. The two false negatives
222 from the RSP method when compared to the Abbott RealTime SARS-CoV-2 Assay, which
223 includes NA purification, had high CN values. However, samples with higher CN values were
224 detected thus sample-specific inhibition may also have played a role.

225

226 There were two false positive results from the RSP method when compared to the Abbott
227 RealTime SARS-CoV-2 Assay. A single target was detected in both cases with Ct values above
228 35. This may represent contamination events or the samples may have viral RNA at levels near
229 the limit of detection for both assays. NA contamination in the laboratory is monitored for by
230 frequent testing of environmental swabs and reagent blanks. Multiple negative controls are also
231 included in each run.

232

233 The intra-assay repeatability assessment of mean Ct values for the three Allplex™ 2019-nCoV
234 targets showed a coefficient of variance of 1.14%. The inter-assay repeatability assessment of
235 mean Ct values after 7 days of sample storage showed a coefficient of variance of 1.27%.

236

237 The relative analytical sensitivity of the Allplex™ 2019-nCoV assay after RSP was found to
238 be 807 RNA copies per reaction. This was calculated from the 8.07-fold decrease in analytical
239 sensitivity of the RSP method compared to NucliSENS® easyMag® NA purification-based
240 testing, which has an analytical sensitivity of 100 RNA copies per reaction as per the Allplex™
241 2019-nCoV assay package insert. The relative decrease was determined by serially diluting and
242 testing a sample with multiple replicates as shown in Table 4. This relative loss in analytical
243 sensitivity can largely be explained by the decrease sample input volume for RSP.

244 NucliSENS® easyMag® NA purification concentrates sample nucleic acids by a factor of
 245 approximately 2, based on sample input versus elution volume. Additionally, the Allplex™
 246 2019-nCoV assay input volume after NA purification is 8µl versus the 3µl sample input volume
 247 for RSP. Thus, the expected loss in analytical sensitivity would be 5.3-fold which is
 248 comparable to the experimentally determined loss of 8.07-fold and suggests that sample
 249 inhibition plays a minor role. Raw data is shown in the S2 Appendix.

250

251 **Table 4. Relative analytical sensitivity assessment**

Dilution	Replicates	Seegene Allplex™ 2019-nCoV Assay RSP Method Percentage of Samples Positive	Seegene Allplex™ 2019-nCoV Assay NA Purification Percentage of Samples Positive
1:20	24	100%	Not done
1:40	24	95.8%	Not done
1:80	24	70.8%	Not done
1:120	24	58.3%	Not done
1:160	24	41.7%	Not done
1:200	10	Not done	100%
1:320	24	33.3%	Not done
1:400	10	Not done	100%
1:500	10	Not done	90%
1:625	10	Not done	70%
1:2000	10	Not done	60%
1:5000	10	Not done	30%

252

253 The performance characteristics were deemed acceptable for clinical diagnostic use in the
254 Groote Schuur Hospital Virology Diagnostic Laboratory and allowed the laboratory to increase
255 the number of samples tested daily by a factor of 5-10 due to the decreased supply chain
256 dependence and simplified workflow. The reduced processing time further facilitated a more
257 rapid test turnaround time which was beneficial for in-hospital infection control. A stable
258 workflow, not subject to reagent availability dependent variations, also decreased laboratory
259 errors and may allow for improved clinical planning as a result of a stable test turnaround time.

260

261 The implementation of the RSP method in our laboratory initially involved implementation of
262 an earlier version of the protocol, Protocol 1 in the S1 Appendix, where steps were performed
263 manually and an altered master mix formulation was used. This version of the protocol showed
264 significant operator dependency with numerous invalid results occurring when new operators
265 performed the assay. The performance issues were most often related to the mixing of the
266 master mix, which must be thorough, and to delays between assay steps. In particular, master
267 mix with added sample was only stable for a brief period before decay and must thus be rapidly
268 placed on the thermocycler. This operator dependency and fluctuating staff availability
269 motivated for the further automation of the process with liquid handling robots.

270

271 The laboratory approach to result interpretation was also affected by the implementation of the
272 RSP method. The approach to NucliSENS® easyMag® NA purification-prepared samples
273 involved release of numerous inconclusive results, despite multiple target amplification at
274 times, due to the known capacity for sample contamination both on the easyMag® instrument
275 and during processing of swabs. The known decrease in sensitivity of the RSP method and the
276 lack of use of the easyMAG® open system for processing, decreased the number of
277 inconclusive results released by our laboratory.

278

279 NA purification is the gold-standard in sample processing for RT-PCR, however, in the setting
280 of a pandemic with significant pressures on reagent supply chains and the need for a rapid
281 increase in testing capacity, the RSP method described here presented a reasonable alternative
282 and has been implemented as the primary sample preparation method in the Groote Schuur
283 Hospital Virology Diagnostic Laboratory in South Africa.

284

285 **References**

286

- 287 1. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, Zhao X, Huang B, Shi W, Lu R, Niu
288 P. A novel coronavirus from patients with pneumonia in China, 2019. *New England*
289 *Journal of Medicine*. 2020 Jan 24.
- 290 2. World Health Organisation. Coronavirus Disease (COVID-19) Situation Report
291 [Internet]. Geneva: WHO; Data as received by WHO from national authorities by
292 10:00 CEST, 2 August 2020 [cited 2020 August 3]. 16 p. Situation Report – 195.
293 Available from: [https://www.who.int/docs/default-source/coronaviruse/situation-](https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200802-covid-19-sitrep-195.pdf?sfvrsn=5e5da0c5_2)
294 [reports/20200802-covid-19-sitrep-195.pdf?sfvrsn=5e5da0c5_2](https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200802-covid-19-sitrep-195.pdf?sfvrsn=5e5da0c5_2).
- 295 3. Tang YW, Schmitz JE, Persing DH, Stratton CW. The laboratory diagnosis of COVID-
296 19 infection: current issues and challenges. *Journal of clinical microbiology*. 2020 Apr
297 3.
- 298 4. Fomsgaard AS, Rosenstjerne MW. An alternative workflow for molecular detection of
299 SARS-CoV-2–escape from the NA extraction kit-shortage, Copenhagen, Denmark,
300 March 2020. *Eurosurveillance*. 2020 Apr 9;25(14):2000398.

- 301 5. Ladha A, Joung J, Abudayyeh O, Gootenberg J, Zhang F. A 5-min RNA preparation
302 method for COVID-19 detection with RT-qPCR. medRxiv. 2020 Jan 1.
- 303 6. Smyrlaki I, Ekman M, Vondracek M, Papanicoloau N, Lentini A, Aarum J, Muradrasoli
304 S, Albert J, Högberg B, Reinius B. Massive and rapid COVID-19 testing is feasible by
305 extraction-free SARS-CoV-2 RT-qPCR. medRxiv. 2020 Jan 1.
- 306 7. Abbasi J. The promise and peril of antibody testing for COVID-19. JAMA. 2020 May
307 19;323(19):1881-3.
- 308